FIG. 1a



Cell viability %
120
100
80
60
40
20
0
1
2
3
4
5
6
7
8
9
10

FIG. 1b



O
3.0
2.5
2.0
1.5
1.0
0.5
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1

FIG. 2a



120
100
80
60
40
20
0
Cell viability %
1
2
3
4
5
6
7
8
9
10

FIG. 2b



3,0
2,5
2,0
1,5
1,0
0,5
0,0
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1

FIG. 3a



120
100
80
60
40
20
0
Cell viability %
1
2
3
4
5
6
7
8
9
10

FIG. 3b



3.0
2.5
2.0
1.5
1.0
0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1

FIG. 4a



120
100
80
60
40
20
0
Cell viability %
1
2
3
4
5
6
7
8
9
10

FIG. 4b



3,0
2,5
2,0
1,5
1,0
0,5
0,0
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1

FIG. 5a



Control
Gefitinib
Cpd1
Gefitinib + Cpd 1

FIG. 5b



90
80
70
60
50
40
30
20
10
0
*
*
*
A
B
C
D

FIG. 6a




Control
Osimertinib
Cpd 1
Osimertinib + Cpd 1

FIG. 6b


90,00
80,00
70,00
60,00
50,00
40,00
30,00
20,00
10,00
0,00
A
B
C
D

FIG, 7a



Control
Gefitinib
Cpd1
Gefitinib + Cpd 1

FIG. 7b



100
90
80
70
60
50
40
30
20
10
0
A
B
C
D

FIG. 8a



Control
Osimertinib
Cpd 1
Osimertinib + Cpd 1

FIG. 8b



100
90
80
70
60
50
40
30
20
10
0
A
B
C
D

FIG. 9



Cell titer glo (RFU)
0
10
20
30
-2
0
2
4
6
Compounds Log (nM)

FIG. 10



Cell titer glo (RFU)
0
10
20
30
-2
0
2
4
6
Compounds Log (nM)

FIG. 11




Compound 1 (nM)
0
30
100
300
1000
3000
10000
p-EGFR (Y1068)
EGFR
p-Paxillin (Y118)
Paxillin
Actin

FIG. 12


Control
Comp.1
AZD9291
Erlotinib
Comp. 1 +AZD9291
Comp. 1 +Erlotinib
1 μM
p-EGFR
EGFR
p-STAT3
STAT3
p-Paxillin
Paxillin
p-AKT
AKT
p-ERK
Actin